RedChip Companies. Inc. Enter your email address to receive our weekly newsletter.

  • RedChip's Top 20 Stock Picks Averaged Over 200% Returns

  • Actinium Commences Trading on NYSE MKT under the Symbol ATNM

    ATNM’s lead product, Iomab-B, is being readied for a single pivotal Phase 3 U.S. clinical trial for preparing patients for a bone marrow transplant

    Actimab-A is in a Phase 1/2 U.S. clinical trial for AML

    APIT platform co-developed with Sloan–Kettering can deliver multiple blockbuster drugs

    Expert management team and world class Scientific Advisory Board

  • At consumers can:

    Research the current market value for small consumer electronics that they are interested in selling, based on the make, model and condition of each item.

    Efficiently find and compare offers for those items from top-rated buyers.

    Review satisfaction ratings and customer reviews of each buyer.

    Accept an offer and complete their transaction on our website directly with the buyer of their choice.

  • CGIX Announces Launch of CALR Mutation Analysis Test to Assist in Diagnosis of Acute Leukemias & Myeloproliferative Neoplasms Read More
    Why Did John Papajohn, the Founder of Caremark, Invest $12 Million in Cancer Genetics (NasdaqCM: CGIX)?
    Redchip Target Price: $44.50
    Click here for company report

    "CGIX has groundbreaking tests in combined $15 billion global market for hematologic, urogenital, and HPV-associated cancers."

    "Five proprietary oncology tests launched, proving ability to launch and gain test approval; Eight tests in development provide diversification and risk reduction."

    "Proprietary tests provide more accurate risk assessment and improved treatment options."

    "New targeted cancer drugs for CLL require combination treatments; we believe adoption of these drugs will drive sales of MatBA®-CLL/SLL."

  • Quadrant 4 Systems (OTC QB: QFOR)
    Record 2013 Financial Results: Revenue Increased 41% and EBITDA Increased 46% Year-Over-Year

    "QFOR's healthcare exchange platform (QHIX) projected to reach a yearly run rate of $48 million in revenue by end of 2014."

    "Quadrant 4 Systems Corporation is an IT software company that develops and implements mission-critical cloud-based enterprise systems for both Fortune 500 companies and smaller enterprises."

    "QFOR's new healthcare exchange is expected to generate substantial revenue over the next 24 months."

    "2015 revenue projection of $128 Million and $35.1 Million in EBITDA. "
    Redchip Target Price: $7.00
    Click here for full report

  • Why is LTTC's Prison Management Systems Platform (Now Serving 50,000 Inmates) Rapidly Growing?
    Redchip Target Price: $0.77
    Click here for report update

    "LTTC's technology is a complete turn-key cloud based solution for inmate management and provides an investigative tool set for corrections facilities."

    "Lattice Incorporated provides advanced information and communications technology solutions to corrections facilities globally"

    "The Company's communication platform is now in 50 facilities in the U.S., Canada, Europe, Japan, and the Caribbean, serving 50,000 inmates."

  • StarStream's (OTC QB: SSET) Ability to Select Winning, Profitable Films Has Enabled Them to Align With Some of the Biggest Players in the Film Industry
    Mid-size production company with equity investments in major films including Lee Daniels "The Butler", "Life of Crime",and "Life After Beth".

    "All star management team comprised of industry veterans."

    "Partnered with William Morris Endeavor."

  • Why is the man who sold ImClone Systems to Eli Lilly for $6.5 billion Chairman of Senesco Technologies?
    "A fair valuation based on industry comparisons (see below) would put the stock at $100+ market cap or approximately nine times its current price."

    "The Chairman of the Board of Directors of Senesco Technologies is Dr. Harland Waksal, who is founder and former CEO, President, Executive VP and COO of ImClone Systems Inc."

    The company's current market cap of
    $13.8 Million is substantially lower than many public companies with cancer drugs in phase 1 clinical trials."

    Ticker Name Phase Price Mkt Cap (M)
    RGLS Regulus Theraputics Inc Pre-Clinical 7.20 297.7
    SLNCF Silence Theraputics Plc 1,2 4.17 196.0
    MRTX Mirati Therapeutics Inc 1,2 17.27 233.8
    AGIO Agios Pharmaceuticals Inc 1 25.71 799.0
    SNTI Senesco Technologies Inc 1,2 4.50 13.8
  • InterCloud Systems (NasdaqCM: ICLD):
    Full-Year 2013 Revenue Increased 201% to $51.4 Million.
    Click For Revenue Report
    "Revenue for the third quarter ended September 30, 2013 increased by $13.2 million, or 448%, to 16.2 million, as compared to $3.0 million for the third quarter of 2012."

    "Net income for the third quarter of 2013 was $1.3 million, or $0.26 basic earnings per share, and $0.12 diluted earnings per share, compared to a net loss of $0.8 million, or $2.16 per share, in the third quarter of 2012."

    "InterCloud is projecting $60M in revenue this year with $6M in EBIDTA."
  • GlyEco, Inc. (OTC QB:GLYE) Development and Large-Scale Commercialization of Treatment Solutions for the Multibillion-Dollar Ethylene Glycol Waste Market
    Redchip Target Price: $4.08
    Click here for full report

    "GlyEco, Inc. is a cleantech innovator formed in 2006 to roll out its proprietary and patent-pending recycling technology, branded GlyEco Technology, which transforms hazardous waste glycols into profitable green products. "

    "GLYE developed a proprietary, patent-pending recycling technology that addresses a multibillion-dollar unmet market need."

    "GLYE is a first mover in this market with limited competition from established ethylene glycol producers."

  • Veriteq (OTC QB: VTEQ) Projecting Break Out Year in 2014: Core Technology: implantable radio frequency (RF) microchip technology, over 100 Patents, Patent Pendings and Licensed Applications.
    "VeriTeQ provides proprietary, innovative healthcare solutions for Unique Device Identification and Bio-Sensing applications."

    "FDA Guidance creates a standard for any future human implantable RFID microchips based on VeriTeQ's technology."

    Bio-sensing technologies for radiation dosimetry provide real-time measurements of received radiation dose from the patient, not the machine."

  • Advanced Vaccine Therapeutics (OTCQB: AVTH)
    Why did the National Institutes of Health and Department of Defense Fund Research of Their Prostate Cancer Drug?
    "Fifteen World leading institutions have chosen AV Therapeutic's prostate cancer drug, Capradine, for a Phase I Clinical Trial Led by Howard Scher, Memorial Sloan Kettering Cancer Center."

    "AV Therapeutics has identified and patented a chemo therapeutic drug called Capridine that has shown in preclinical models to have specific activity against prostate and colon cancer."

    "This drug is expected to be the frontline AV Therapeutics product specifically in prostate cancer where limited chemotherapy exists at present."

Small Cap Stocks Microcap Stocks Find us on Google+
join RedChip Plus
Small Cap Stock Information

Quotes, Level II, Charts, News, Profile, Filings and More!


Small Cap Clients by Sectors
Basic Materials
Consumer Goods
Health Care
Industrial Goods
©2014 RedChip Companies, Inc. | "Discovering Tomorrow’s Blue Chips Today." ™ | Disclaimer | Disclosures | Policies